Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063Source: DataRank Database

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies is a research paper published in Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.28)OA: bronzeTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Jibran Ahmed ORCID,Bettzy Stephen ORCID,Sarina A. Piha‐Paul ORCID,Daniel D. Karp ORCID,Abdulrazzak Zarifa ORCID

Live enrichment

PubMed:37864520 PMC:PMC10841432 OpenAlex:https://openalex.org/W4387845646

NIH HHS

Grant: P30CA016672

NCI NIH HHS

Grant: T32 CA101642

NIH HHS

Grant: CA101642

Merck KGaA

Merck

FWCI

4.28

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.35063

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.35063

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.35063

journalhttps://doi.org/10.1002/cncr.35063

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37864520

Fields of Study

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersOvarian cancer diagnosis and treatmentHumansFemaleGenital Neoplasms, FemaleUterine Cervical NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsImmunoglobulin GAntibodies, Monoclonal, Humanized

MeSH Terms

Antineoplastic Combined Chemotherapy ProtocolsUterine Cervical NeoplasmsFemaleGenital Neoplasms, FemaleHumansImmunoglobulin GNeoplasm Recurrence, LocalAntibodies, Monoclonal, Humanized

Keywords

MedicineInternal medicineEndometrial cancerClinical endpointCervical cancerOncologyProgressive diseaseAvelumabInterquartile rangeRadiation therapyResponse Evaluation Criteria in Solid TumorsAdverse effectCancerUrologyGastroenterologyImmunotherapyChemotherapyClinical trialNivolumabOvarian cancerImmune Checkpoint Blockade

Sustainable Development Goals

SDG 0: Good health and well-being

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

FAIR Checklist

Authors (18)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)